E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure and death. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This study has 2 parts: (a) a blinded 52 week phase (Part 1), and (b) an open label phase (Part 2). The primary objective of Part 1 is to evaluate the long term safety of tadalafil 20 mg and 40 mg once daily in the treatment of patients with PAH. The primary objective of Part 2 is to provide continued access to tadalafil for patients completing Part 1.
|
|
E.2.2 | Secondary objectives of the trial |
A secondary objective of Part 1 of the trial is to determine the durability of efficacy of tadalafil 20 mg and 40 mg once daily in the treatment of patients with PAH. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
- For purposes of study entry, clinical worsening is defined as WHO functional class deterioration and documentation of clinical worsening. The following subjects will be eligible to enter the extension trial. • The subject discontinues the placebo-controlled study (LVGY) due to clinical worsening and is on placebo, tadalafil 2.5 mg, 10 mg, or 20 mg. • The subject completes Week 16 in the placebo-controlled study (LVGY), and has one of the following: .No clinical worsening. .Clinical worsening at the Week 16 visit and is receiving placebo, tadalafil 2.5 mg, 10 mg, or 20 mg. - A female subject of childbearing potential must have a negative urine pregnancy test at the screening visit and agree to use two medically reliable methods of contraception (e.g., barrier with spermacide or hormonal contraception) until study completion. - Written informed consent (and written assent for minors) will be obtained prior to any study procedure being performed.
|
|
E.4 | Principal exclusion criteria |
- Are nursing or pregnant. - Have left-sided heart disease, including any of the following: clinically significant aortic or mitral valve disease (i.e., aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation); pericardial constriction; restrictive or congestive cardiomyopathy; left ventricular ejection fraction < 40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography; left ventricular shortening fraction < 22% by echocardiography; life-threatening cardiac arrhythmias; symptomatic coronary artery disease within 5 years of study entry. - Have a systolic blood pressure < 90 mm Hg or diastolic blood pressure < 50 mm Hg at screening. - Have a history of angina pectoris or other condition that was treated with long-or short-acting nitrates within 12 weeks before administration of study drug. - Have a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease besides pulmonary arterial hypertension that may significantly limit ambulation. - Current treatment with antiretroviral therapy (protease inhibitor), sustemic ketoconazole, or systemic itraconazole. - Current treatment with a prostacyclin or analogue, L-arginine, phosphodiesterase inhibitor other than tadalafil, or investigational drug. An exception is allowed in Japan for subjects who participated in placebo-controlled study LVGY while receiving treatment with beraprost sodium. - Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. - Are employed by Lilly or ICOS (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly or ICOS employees may participate in Lilly ICOS LLC-sponsored clinical trials, but are not permitted to participate at a Lilly or ICOS facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Six-minute walk distance and time to WHO functional class deterioration from Day 0 to Week 52. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 3 |